Brain PET Imaging: Frontotemporal Dementia.
Brain PET Imaging: Frontotemporal Dementia.
复制标题
脑 PET 成像：额颞叶痴呆。
DOI：
10.1016/j.cpet.2022.09.010
复制
发表时间：
2023
期刊：
影响因子：
2.6
通讯作者：
Raji,CyrusA
中科院分区：
文献类型：
--
作者：
Ward,Joshua;Ly,Maria;Raji,CyrusA
脑PET在神经退行性疾病，特别是额颞叶痴呆（FTD）的诊断中至关重要，因为其复杂的表现和症状与各种其他神经退行性疾病和精神疾病重叠。与结构MRI相比，18F-FDG-PET具有更高的灵敏度和特异性，当两种成像技术同时使用时，可以获得最佳的诊断结果。与SPECT相比，PET在诊断FTD方面表现出更高的灵敏度，主要是对其他影像学和临床信息的补充。Tau-PET和淀粉样蛋白pet在FTD诊断中的主要用途是区分阿尔茨海默病（AD），尽管这些方法主要局限于研究环境。目前迫切需要为FTD设计的新型PET放射性示踪剂，其潜在靶标包括TAR DNA结合蛋白43 （TDP-43）。
Brain PET is crucial in the diagnosis of neurodegenerative disorders, especially frontotemporal dementia (FTD) due to its complex presentation and constellation of symptoms that overlap with a variety of other neurodegenerative and psychiatric disorders. 18F-FDG-PET has superior sensitivity and specificity compared to structural MRI, with optimal diagnostic results achieved when the two imaging techniques are in tandem. PET has demonstrated improved sensitivity compared to SPECT for FTD diagnosis and is primarily a supplement to other imaging and clinical information. Tau-PET and Amyloid-PET’s primary use in FTD diagnosis is differentiation from Alzheimer’s Disease (AD) although these methods are limited primarily to research settings. A critical need exists for novel PET radiotracers designed for FTD with potential targets that include TAR DNA binding protein 43 (TDP-43).